Screening of target compounds from Fructus Piperis using high α1A adrenoreceptor expression cell membrane chromatography online coupled with high performance liquid chromatography tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 81-82, Issue , 2013, Pages 133-137

  Han, Shengli ^a   Zhang, Tao ^a   Feng, Liuxin ^a   Lv, Nan ^a   Wang, Sicen ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Alpha (1A) cell membrane chromatography; Fructus Piperis; High performance liquid chromatography tandem mass spectrometry; Piperine

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; FRUCTUS PIPERIS EXTRACT; PIPERINE; PLANT EXTRACT; TAMSULOSIN; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ARTICLE; BINDING ASSAY; CELL MEMBRANE CHROMATOGRAPHY ON LIQUID CHROMATOGRAPHY; CHINESE MEDICINE; CHROMATOGRAPHY; CONTROLLED STUDY; DISSOCIATION EQUILIBRIUM CONSTANT; DRUG BINDING; DRUG BINDING SITE; DRUG SCREENING; DRUG STRUCTURE; FOOD; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; ALKALOIDS; BENZODIOXOLES; BINDING SITES; BINDING, COMPETITIVE; CELL MEMBRANE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUGS, CHINESE HERBAL; HEK293 CELLS; HUMANS; MALE; MOLECULAR DOCKING SIMULATION; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONAMIDES; TANDEM MASS SPECTROMETRY;

EID: 84877325203     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.04.001     Document Type: Article

References (11)

1. Pinheiro L.C., Pisco J.M. Treatment of benign prostatic hyperplasia. Tech. Vasc. Interv. Radiol. 2012, 15:256-260.
2. Abdollah F., Briganti A., Suardi N., Castiglione F., Gallina A., Capitanio U., Montorsi F. Metabolic syndrome and benign prostatic hyperplasia: evidence of a potential relationship, hypothesized etiology, and prevention. Korean J. Urol. 2011, 52:507-516.
3. Gruschkus S., Poston S., Eaddy M., Chaudhari S. Adherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia. Pharm. Therapeut. 2012, 37:464-470.
4. Lepor H. The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Rev. Urol. 2006, 8:S3-S9.
5. Lee H.S., Kim S.W., Oh S.J., Choo M.S., Lee K.S. Efficacy and safety of tamsulosin for treating lower urinary tract symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, controlled, open label non inferiority study. Korean J. Urol. 2012, 53:178-183.
6. Nicholson T.M., Ricke W.A. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 2011, 82:184-199.
7. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70:461-477.
8. He L.C., Geng X.D. Determination of ligustilide in rat blood and tissues by capillary gas chromatography/mass spectrometry. New Prog. Biomed. Chromatogr. 1996, 3:8-9.
9. Han S.L., Zhang P., Wei F., Wang S.C. Screening active components acting on a1A adrenergic receptors from agrimony using a Sprague-Dawley rat prostate cell membrane chromatography online coupled HPLC/MS method. Anal. Methods 2012, 4:3351-3357.
10. Han S.L., Zhang T., Huang J., Hu Z.G., Wang S.C. Screening target components from Radix salviae miltiorrhiae using an EGFR/CMC-online-HPLC/MS method. Anal. Methods 2012, 4:1078-1083.
11. Mou J.J., Fang H., Jing F.B., Wang Q., Liu Y.Z., Zhu H.W., Shang L.Q., Wang X.J., Xu W.F. Design, synthesis and primary activity evaluation of l-arginine derivatives as aminopeptidase N/CD13 inhibitors. Bioorg. Med. Chem. 2009, 17:4666-4673.